Comparative susceptibility evolution in Escherichia coli from urinary tract infections in outpatients and inpatients at Perpignan hospital in 2002 and 2004;Évolution comparée de la sensibilité de souches de Escherichia coli isolées d'infections urinaires de patients consultant aux urgences et de patients hospitalisés en 2002 et 2004 à l'hôpital de Perpignan

Pathologie Biologie

Volumn 54, Issue 8-9 SPEC.ISS., 2006, Pages 427-430

  Lemort, M L ^a   Neuville, S ^a   Medus, M ^a   Gueudet, P ^a   Saada, M ^a   Aumaitre H ^a   Lecaillon, E ^a  

^a St Jean Hospital   (France)

Author keywords

Fluoroquinolones r sistance; Urinary Escherichia coli susceptibility

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; NALIDIXIC ACID; NITROFURANTOIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DEVICE; ESCHERICHIA COLI; EVOLUTION; FRANCE; HOSPITAL PATIENT; NONHUMAN; OUTPATIENT; URINARY TRACT INFECTION; CLASSIFICATION; DISEASE PREDISPOSITION; DRUG EFFECT; EMERGENCY HEALTH SERVICE; ENTEROBACTER INFECTION; HUMAN; MICROBIOLOGICAL EXAMINATION; STATISTICS;

ANTI-BACTERIAL AGENTS; DISEASE SUSCEPTIBILITY; EMERGENCY SERVICE, HOSPITAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FRANCE; HUMANS; INPATIENTS; MICROBIAL SENSITIVITY TESTS; OUTPATIENTS; URINARY TRACT INFECTIONS;

EID: 33750916169     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.07.007     Document Type: Article

References (14)

1. Bryskier A. Les fluoroquinolones. Antibiotiques : agents antibactériens et antifungiques (1999), Ellipses, Paris
2. Recommandations et références médicales de l'ANDEM. Concours Médical. 1996;40(suppl du 30/11/1996):1-9.
3. Lecaillon E., Blosser-Middleton R., Sahhm D.F., and Jones M.E. Activité de l'acide nalidixique et des fluoroquinolones sur des souches de Escherichia coli isolées d'infections urinaires non compliquées (réseau TSN-France, 1999-2001). Med. Mal. Infect. 34 (2004) 450-454
4. Garau J., Xercavins M., Rodriguez-Caballeira M., Gomez-Vera J.R., Coll I., Vidal D., et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the Community. Antimicrob. Agents Chemother. 43 11 (1999) 2736-2741
5. Perea S., Hidalgo M., Arcediano A., Ramos M.J., Gomez C., Hornedo J., et al. Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. J. Antimicrob. Chemother. 44 (1999) 117-120
6. Oteo J., Campos J., Baquero F., and Spanish members of the European Antimicrobial Resistance Surveillance System (EARSS). Antibiotic resistance in 1962 invasive isolates of in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System 2001. J. Antimicrob. Chemother 50 (2002) 945-952
7. Clifford Mc Donald L., Feng-Jui C., Hsiu-Jung L., Hsiao-Chuan Y., Po-Liang L., Cheng-Hua H., et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob. Agents Chemother 45 11 (2001) 3084-3091
8. Putman S.D., Sanders J.W., Tribble D.R., Rockabrand D.R., Riddle M.S., Rozmajzl P.J., et al. Posttreatment changes in Escherichia coli antimicrobial susceptibility rates among diarrheic patients treated with ciprofloxacin. Antimicrob. Agents Chemother. 45 6 (2005) 2571-2572
9. Maslow J, Lee B, Lautenbach E. Fluoroquinolone-resistant Escherichia coli carriage in Long-term care facility. Emerg Infect Dis [serial online] 2005 Vol 11 N° 6; 889-894 http: www. Cdc.gov/eid.
10. Pena C., Albareda J.M., Pallares R., Pujol M., Tubau F., and Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. J. Antimicrob. Agents Chemother 39 2 (1995) 520-524
11. Goettsch W., Van Pelt W., Nagelkerke N., Hendrix M.G.R., Buiting A.G.M., Petit P.L., et al. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J. Antimicrob. Chemother. 46 (2000) 223-228
12. Vatopoulos AC, Kalapothaki V, Legakis NJ. Bacterial resistance to ciprofloxacin in Greece: results from the National Electronic Surveillance System. Greek network for the surveillance of antimicrobial resistance. Emerg Infect Dis 1999;5(3):471-6, http: www.Cdc.gov/eid.
13. Cizman M., Orazem A., Krizan-Hergouth V., and Kolman J. Correlation between increased comsumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections J. Antimicrob. Chemother 47 (2001) 502-503 [Correspondence]
14. Galas M, Manson J, Pangon B, Scemama P, Billon C. Évolution de la sensibilité aux antibiotiques du pneumocoque et de E. coli en ville et à l'hôpital : analyse des résultats entre 2001 et 2004 dans les Yvelines. 343/63 P RICAI 2005 [Abstracts].